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Abstract
Background: Although considerable progress has been made in the treatment of chronic kidney disease, compromised
quality of life continues to be a significant problem for patients receiving hemodialysis (HD). However, in spite of the high
prevalence of sleep complaints and disorders in this population, the relationship between these problems and quality of
life remains to be well characterized. Thus, we studied a sample of stable HD patients to explore relationships between
quality of life and both subjective and objective measures of nocturnal sleep and daytime sleepiness
Methods: The sample included forty-six HD patients, 24 men and 22 women, with a mean age of 51.6 (10.8) years.
Subjects underwent one night of polysomnography followed the next morning by a Multiple Sleep Latency Test (MSLT),
an objective measure of daytime sleepiness. Subjects also completed: 1) a brief nocturnal sleep questionnaire; 2) the
Epworth Sleepiness Scale; and, 3) the Quality of Life Index (QLI, Dialysis Version) which provides an overall QLI score
and four subscale scores for Health & Functioning (H&F), Social & Economic (S&E), Psychological & Spiritual (P&S), and
Family (F). (The range of scores is 0 to 30 with higher scores indicating better quality of life.)
Results: The mean (standard deviation; SD) of the overall QLI was 22.8 (4.0). The mean (SD) of the four subscales were
as follows: H&F – 21.1 (4.7); S&E – 22.0 (4.8); P&S – 24.5 (4.4); and, F – 26.8 (3.5). H&F (rs = -0.326, p = 0.013) and F (rs
= -0.248, p = 0.048) subscale scores were negatively correlated with periodic limb movement index but not other
polysomnographic measures. The H&F subscale score were positively correlated with nocturnal sleep latency (rs = 0.248,
p = 0.048) while the H&F (rs = 0.278, p = 0.030) and total QLI (rs = 0.263, p = 0.038) scores were positively associated
with MSLT scores. Both of these latter findings indicate that higher life quality is associated with lower sleepiness levels.
ESS scores were unrelated to overall QLI scores or the subscale scores. Subjective reports of difficulty falling asleep and
waking up too early were significantly correlated with all four subscale scores and overall QLI. Feeling rested in the
morning was positively associated with S&E, P&S, and Total QLI scores.
Conclusion: Selected measures of both poor nocturnal sleep and increased daytime sleepiness are associated with
decreased quality of life in HD patients, underscoring the importance of recognizing and treating these patients' sleep
problems.
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Background
Considerable progress has been made in the treatment of
chronic kidney disease (CKD). Yet, suboptimal quality of
life continues to be a significant problem for patients
receiving hemodialysis (HD). Several factors are believed
to contribute to this problem including stress [3-5],
depression and anxiety [6], anemia [7-9], the confines of
treatment [3,10], and vocational inactivity [7]. Sleep com-
plaints and daytime sleepiness are also very prevalent in
this group [11,12], but their impact upon quality of life
remains to be well characterized. In the general popula-
tion, nocturnal and daytime sleep abnormalities adversely
affect quality of life-related measures such as general
health status [13], satisfaction with life [14], mood [15]
and work performance [16]. Because sleep problems, such
as insomnia, sleep apnea, and periodic limb movement
disorder (see Table 1) are very prevalent in the HD popu-
lation, information about their association with life qual-
ity is essential for the optimization of both interventions
and clinical outcomes. Here we present a systematic
exploration (that was part of a larger study previously
reported [17]) of how quality of life is related to specific
measures of nocturnal sleep and daytime sleepiness in a
sample of stable HD patients. Our hypothesis was that
reduced quality of life would be associated with poorer
nocturnal sleep and increased daytime sleepiness.
Methods
Sample
The School of Medicine's Internal Review Board and
appropriate HD unit physicians and administrators
approved the protocol. Because we sought to study rela-
tionships among quality of life and sleep variables in
patients with CKD receiving intermittent HD independ-
ent of the effects of other major chronic illnesses, poten-
tial subjects with histories of cardiac disease, chronic lung
disease, arthritis, organic brain disease, drug/alcohol
abuse, or past psychiatric disorders [1] requiring treat-
ment were excluded from participation. Because of poten-
tial drug-related effects on sleep and wakefulness [18],
those subjects routinely taking medications known to
modulate central nervous system state such as beta-block-
ers (low lipid-soluble agents were allowed, e.g. atenolol),
other antihypertensives such as clonidine and
methyldopa, and antidepressants, sedatives, hypnotics,
activating agents, or pain medications were also excluded.
Finally, potential subjects were screened via a structured
interview to exclude those with a history of or current
treatment for sleep apnea syndrome, restless legs syn-
drome, or periodic limb movement disorder. The final
sample included 46 stable, otherwise healthy HD patients
recruited from 26 HD units in the Atlanta metropolitan
area (see Table 2). According to Cohen [19], using a one-
tailed test and an alpha level = 0.05, a sample of 46 pro-
vided a power of approximately 85% to detect a medium
effect size (rs = 0.40).
Demographic and Clinical Features of the Sample
Demographic, clinical, and dialysis related information
was obtained via chart review. Monthly laboratory reports
were collected for three months immediately prior to
inclusion and the values cited in this report represent the
means (± SD; standard deviation) for this period. Excep-
tions include parathyroid hormone (PTH intact) and fer-
ritin, which were measured once during the three-month
period. Body mass index (BMI) was calculated using the
patient's estimated dry weight (ideal weight at optimal
fluid balance) at the time of consent. All subjects received
HD three times a week on one of three shifts (based on
when a majority of their treatment occurred; shift 1 – 6 am
to 10 am; shift 2 – 10 am to 2 pm; shift 3 – 2 pm to 6 pm)
for periods of three to five hours. All subjects were meta-
bolically stable and adequately dialyzed [20] (see Table
2).
Evaluation of Nocturnal Sleep and Daytime Sleepiness
On the night of a HD treatment day (i.e., 6 to 12 hours
post treatment), all subjects were asked to complete brief
nocturnal and daytime sleep questionnaires and to
undergo one night of laboratory-based nocturnal polys-
omnography (PSG) followed by a daytime PSG nap study
(Multiple Sleep Latency Test; MSLT). These subjective and
objective measures target the most common nocturnal
and daytime sleep complaints and primary sleep disorders
seen in HD patients [21](see Table 3).
The questionnairse asked subjects to estimate the amount
of sleep they typically obtained each night over the past
six months. In addition, they were asked to rate, on a scale
from 1 (rarely) to 5 (always), the following: how often
they had trouble falling asleep, waking up during the
night, and waking up too early and not being able to fall
asleep again; how often they felt rested in the morning;
how often they napped; and, how often they awoke at
night from kicking of the legs and gasping/choking. If the
subject marked the "do not know" option, the response
was coded 0 (missing data). Content validity of the ques-
tionnaire is supported by the fact that it targeted major
domains of subjective sleep quality measured by several
other sleep instruments [22-26] and included specific
questions used in a large population-based study of sleep
[27]. In addition, it captured perceptions of two polysom-
nographic measures of interest in this population – limb
movements and apneas (see Table 3). Subjects also com-
pleted the Epworth Sleepiness Scale (ESS), an inventory
designed to evaluate a patient's general level of subjective
sleepiness – or more specifically, chance of dozing in real
life situations [28,29]. The range of possible scores on the
ESS is 0 to 24, with higher scores indicating greater levelsHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/68
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of subjective sleepiness. A score > 11 is often used to iden-
tify individuals with significant subjective sleepiness lev-
els [30]. Acceptable validity, test-retest reliability, and
internal consistency reliability of the ESS have been
reported [28,29].
The PSG consisted of a standard montage (electrode
placement) of electroencephalography (EEG) (C3/A2 or
C4/A1 and O2/C3 or O1/C4), monopolar left and right
electrooculography (EOG) referenced to the opposite
mastoid, surface mentalis electromyography (EMG), res-
piratory airflow and effort, electrocardiography (ECG),
anterior tibialis EMG, and pulse oximetry. All recordings
were made on a Grass Model 78 polysomnograph
recorded with a paper speed of 10 mm/sec and scored in
30-second epochs. Sleep variables calculated for each sub-
ject included: Total sleep time (TST, minutes); sleep effi-
ciency (SE = TST/time in bed × 100); the percentage of TST
spent in stages 1, 2, 3 & 4, and REM (rapid-eye-move-
ment) sleep [31]; and the latency to three consecutive
epochs of sleep (sleep latency, SL, minutes). Periodic leg
movements and movements with arousals [32], apneas,
and total brief arousals [33] were scored using
conventional criteria. The brief arousals, apneas, limb
movements, and limb movements with arousals observed
were expressed as the number of events per hour of sleep.
All PSGs were scored by the same certified polysomno-
graphic technician and verified by the Director of the
Sleep Disorders Center.
The morning following the nocturnal PSG, daytime sleep-
iness was quantified using the Multiple Sleep Latency Test
(MSLT) following standard procedures [34]. Approxi-
mately 1.5 to 2 hours after awakening, subjects were
allowed five 20 – minute nap opportunities at 2-hour
intervals across the day. The SL on any given nap opportu-
nity was defined as the time from lights out to the first 30-
second epoch scored as sleep. Each nap was terminated
after 20 minutes or after a maximum of 15 minutes from
sleep onset. The average SL across all naps was calculated
and expressed as the mean sleep latency. The range of pos-
sible mean sleep latency scores on the MSLT is 0 to 20
minutes, with a low score indicating greater sleepiness.
According to the International Classification of Sleep Dis-
orders (ICSD), a mean sleep latency ≤ 5 minutes suggests
"severe or pathological" sleepiness, a mean sleep latency
between 5 minutes and 10 minutes suggests "moderate
sleepiness", and a mean sleep latency > 10 minutes sug-
gests "mild or normal sleepiness". An alternative schema
also used to interpret MSLT scores is based on supporting
evidence derived from comparisons of normal subjects to
patients with sleep abnormalities[15,35-37] and uses a
MSLT score < 8 minutes as indicative of abnormal
sleepiness.
Evaluation of Quality of Life
Quality of life was defined as a person's sense of well-
being reflecting satisfaction or dissatisfaction with the
areas of life that are deemed important. Immediately
before the nocturnal PSG, all subjects completed the
Quality of Life Index (QLI, Dialysis Version) developed by
Table 1: Definitions of Sleep Variables Measured in the Study [1,2]
Brief Arousal – An abrupt change (3 to 14 seconds) from a "deeper" stage of NREM sleep to a "lighter" stage, or from REM sleep to wakefulness.
Brief Arousal Index – number of brief arousals/hour of sleep; normally < 15/hour
Excessive Daytime Sleepiness – Difficulty in maintaining the alert, awake state. Can be measured subjectively using questionnaires (such as the 
Epworth Sleepiness Scale; see text) or objectively (polysomnographically) using the Multiple Sleep Latency Test (see text).
Insomnia/Sleep Fragmentation (subjective) – difficulty initiating or maintaining sleep; often characterized by difficulty falling and/or staying 
asleep, early morning awakenings, or unrefreshing sleep.
Mean Sleep Latency – the average period of time from the start of a nap opportunity to the first epoch of sleep as measured by the Multiple 
Sleep Latency Test.
Periodic Limb Movement – a rapid partial flexion of the foot at the ankle, extension of the big toe, and partial flexion of the knee and hip[ that 
occurs during sleep. The movements occur with a periodicity of 5 to 90 seconds, lasting 0.5 to 5.0 seconds.
Periodic Limb Movement Index (PLMI) – number of periodic limb movements/hour of sleep.
Periodic Limb Movement with Arousal Index – number of limb movements/hour of sleep associated with an abrupt change from a deeper 
stage of NREM sleep to a lighter stage, or from REM sleep to wakefulness
Respiratory disturbance – Cessation (apnea) or reduction in breathing (hypopnea; airflow reduced by at least 50%) during sleep, lasting 10 
seconds or longer, often associated with a fall in blood oxygen saturation.
Respiratory Disturbance Index (RDI) – number of apneas/hypopneas per hour of sleep.
Sleep Efficiency (SE) – The proportion of sleep in the episode filled by sleep; the ratio of TST to time in bed. Normal values range typically from 
80% to 95% and decrease with age.
Sleep Latency (SL) – The onset of sleep defined as the first of three consecutive epochs of Stage 1 sleep or the first epoch of any other stage of 
sleep. Normal sleep latency averages < 20 minutes.
Total Sleep Time (TST) – The amount of actual sleep time in a sleep episode; the time is equal to the total sleep episode less the awake time; 
average normal TST is 7.5 hours.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/68
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Ferrans and Powers [38,39], a questionnaire consisting of
64 items divided into two sections. The first section
assesses how satisfied the subject is with 32 aspects of life
while the second assesses the importance of those same
aspects. Responses to the satisfaction items range from
"very satisfied" (6) to "very dissatisfied" (1). Responses to
the importance items range from "very important" (6) to
"very unimportant" (1). Scores are calculated by weight-
ing each satisfaction response with its paired importance
response. Overall QLI scores and four subscale scores are
calculated: Health & Functioning, Social & Economic, Psy-
chological & Spiritual, and Family. The range of scores on
the overall scale and the subscales scores is 0 to 30 with a
higher score indicating a better quality of life.
Table 2: Demographic/Clinical/Dialysis-Related Features of the Sample
Demographic Variables Mean (SD*) or n** Median Range
Age 51.6 (10.8) 52.0 32.0 to 74.0
Gender (n)
• Males 24
• Females 22
Race (n)
• Black 36 -- --
• White 10
Marital Status (n)
• Married 27 -- --
• Divorced 4
• Single 15
Years of Education 12.3 (2.0) 12.0 7.0 to 18.0
Clinical Variables
Etiology of Renal Failure (n)
• Diabetes 15 -- --
• Hypertension 22
• Glomerulonephritis 3
• Other 6
BUN (mg/dL) 65.0 (16.8) 63.0 39.3 to 105.0
Creatinine (mg/dL) 12.0 (2.8) 12.4 3.6 to 17.5
Sodium (meq/L) 139.9 (3.0) 139.5 132.3 to 147.3
Potassium (meq/L) 4.9 (0.7) 4.6 3.8 to 6.4
CO2 (meq/L) 20.6 (2.8) 20.7 13.8 to 27.7
Calcium (mg/dL) 9.5 (0.8) 9.6 7.5 to 11.4
Phosphorous (mg/dL) 5.4 (1.5) 5.3 2.8 to 10.5
Hematocrit (%) 35.8 (3.2) 36.2 28.9 to 43.2
Ferritin (µ/L) 549.1 (394.3) 515.0 13.4 to 1764.0
PTH (pg/ml) 222.9 (197.7) 184.5 13.0 to 1144.0
Body Mass Index (kg/m2) 26.8 (5.6) 26.8 17.0 to 40.1
• Black Males (n = 18) 25.8 (5.1) 18.8 to 36.8
• Black Females (n = 18) 28.0 (5.8) 17.0 to 40.1
• White Males (n = 6) 25.3 (6.1) 20.7 to 36.6
• White Females (n = 4) 27.3 (7.1) 18.3 to 35.5
Days hospitalized 2.2 (3.3) 0 0 to 12
Dialysis Variables
Kt/V 1.5 (0.3) 1.5 1.1 to 2.6
Treatment time (minutes) 219.0 (24.1) 220.0 165.0 to 270.0
Shift
• 1 18 -- --
• 2 13
• 3 15
Months on HD 37.5 (36.0) 28.5 5.0 to 184.0
* SD = standard deviation, ** = numberHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/68
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The instrument has excellent validity and reliability [38].
Content validity was established by administering a ques-
tionnaire that included sixty-four items applicable to both
healthy graduate students and dialysis patients (n = 88).
Six items relative to dialysis were added and the instru-
ment was administered to dialysis patients (n = 37). Cor-
relations between the instrument and an overall
satisfaction with life question of 0.75 (graduate students)
and 0.65 (dialysis patients) supported criterion-related
validity. Support for reliability was provided by test-retest
correlations of 0.87 (graduate students) and 0.81 (dialysis
patients) and Cronbach alphas of 0.93 (graduate stu-
dents) and 0.90 (dialysis patients)[40].
Data Analysis
Descriptive statistics were used to summarize all data.
Because examination of the data revealed that they did not
meet the assumption of normality necessary for the use of
parametric statistical tests, nonparametric procedures
were used. Differences in quality of life scores in groups of
patients based on categorical variables were detected
using the Mann Whitney-U (two categories) or the
Kruskal-Wallis (three or more categories) procedures [41].
Correlations between quality of life scores and interval/
ratio/ordinal measures were performed using the Spear-
man rho (rs) correlation procedure (one-tailed test; our
hypothesis was that poorer nocturnal sleep and increased
daytime sleepiness would be associated with decreased
quality of life) [41]. Internal consistency reliability of the
QLI in this sample was supported by Cronbach's alphas of
0.91 for the overall scale and 0.80, 0.94, 0.81, and 0.91,
respectively, for the Health & Functioning, Social &Eco-
nomic, Psychological & Spiritual, and Family subscales.
Results were also similar to those previously reported in a
larger, more representative sample of HD patients (see
Table 4) [38]. The significance level was set at α = 0.05.
Because of the exploratory nature of this study, we chose
not to use the Bonferroni correction for multiple correla-
tions and to accept the greater possibility of making a
Type II error [22].
Results
The demographic, clinical, and dialysis-related features of
the sample are included in Table 2. Similar to national sta-
tistics for HD patients [42], the mean age was 51.6 (10.8)
years with a relatively even gender distribution; diabetes
and hypertension were the most common causes of CKD.
Unlike the national population of HD patients, a majority
of subjects in this sample were black reflecting the racial
composition of the available population. Subjects had a
relatively high level of education because of the need to
read and complete study questionnaires.
The mean total QLI and the four subscale scores are
reported in Table 4. Overall QLI, the Health & Function-
ing, and the Psychological & Spiritual scale scores were
significantly higher than those reported by Ferrans &
Power (t-test) in a larger randomly selected sample of HD
patients [38], probably reflecting the overall stable condi-
tion and otherwise general good health of this sample.
Also similar to the Ferrans & Powers study, subjects were
most satisfied with their Family quality of life; relation-
ships among children/spouses/significant others and fam-
ily's happiness were both the most satisfying and most
important. Correlations between items of satisfaction and
importance regarding children (rs = 0.41, df = 44, p =
0.005), family (rs = 0.28, df = 44, p = 0.038), and spouse
(rs = 0.61, df = 44, p = 0.000) were statistically significant.
Health & Functioning life quality was the least satisfying
and job satisfaction, ability to travel, and amount of
stress/worries in life ranked lowest in this regard. How-
ever, these items were also among the least important,
possibly reflecting adjustment to the life constraints
imposed by the disease and its treatment [38].
Table 3: Common Sleep Problems/Disorders in Hemodialysis Patients: Comparison of Subjective and Objective Measures
Problem Subjective (prior six months) Objective (one night of PSG and daytime MSLT)
Insufficient sleep Amount of sleep typically obtained Total sleep time
Insomnia/Sleep Fragmentation Difficulty:
• Falling asleep Nocturnal sleep latency
• Staying asleep Sleep efficiency
• Early morning awakenings Arousals
• Unrefreshing sleep
Daytime sleepiness Frequency of daytime napping Nocturnal sleep latency
Epworth Sleepiness Scale Multiple Sleep Latency Test
Periodic Limb Movement Disorder Waking from legs kicking Periodic limb movements/hour
Sleep Apnea Syndrome Waking from gasping/choking Apneas/hour
PSG = polysomnography, MSLT = Multiple Sleep Latency TestHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/68
Page 6 of 10
(page number not for citation purposes)
There were no significant differences in total QLI or sub-
scale scores in groups of subjects based on gender, race,
marital status, etiology of renal failure, or treatment time
of day. There were also no significant relationships
detected between these scores and age, years of education,
the number of days hospitalized in the past year, or other
parameters measured listed in Table 2.
Data from the nocturnal and daytime sleep question-
naires are presented in Table 5. Subjects estimated sleep-
ing an average of 6.3 hours (377.7 ± 78.9 minutes) per
night and most reported having difficulty falling asleep,
waking up at night, or waking too early in the morning
"sometimes". Subjects were typically unaware that their
legs kicked during the night and only rarely experienced
gasping or choking. Most subjects reported that they also
"sometimes" napped and felt rested during the day. The
mean ESS Scale score was 7.4 ± 4.6 suggesting normal sub-
jective daytime sleepiness levels. However, 30.4% (n =
14) had scores ≥ 11, suggesting that clinically significant
sleepiness was a problem for many of the subjects [17].
Data from the nocturnal PSGs are presented in Table 6.
The mean TST for the group was 5.6 hours (335.8 ± 64.8
minutes) with a SE of 78.2% ± 14.0, values lower than
normative data reported for individuals of the same gen-
der and similar in age [43] but consistent with the results
of other PSG studies in HD patients [44,45]. General fea-
tures of nocturnal sleep, including percentage of time
spent in the various stages of sleep, were unremarkable.
Mild sleep apnea (RDI < 15 apnea/hour) [2] and periodic
limb movement disorder (PLMI < 25 limb movements/
hour) [1] characterized the group despite clinical screen-
ing to eliminate subjects with these problems. The average
MSLT score was 10.2 ± 4.2 minutes; 15 of the subjects
(32.6%) had scores less than 8 minutes and 6 (13.0%)
had pathologic daytime sleepiness (MSLT scores < 5 min-
utes), indicating that objectively measured daytime
sleepiness was also a problem for many of the subjects
[1,15,17,36,37]. There were no significant univariate rela-
tionships noted between subjective and objective meas-
ures of sleep.
The correlations between the quality of life scores and
subjective and polysomnographic nocturnal/daytime
sleep variables appear in Table 7. Increased perceived dif-
ficulty falling asleep and waking up early in the morning
were negatively associated with total QLI scores and all
four subscale scores. Feeling more rested in the morning
was positively associated with Social & Economic (rs =
Table 4: Quality of Life Index Scores Reported by HD Sample in This Study and by HD Patients Studied by Ferrans/Powers*
Scale Study Sample (n = 46) Ferrans &Powers Study (n = 349)*
Mean (SD) Range Internal Consistency** Mean (SD) Range Internal 
consistency
Health & Functioning Subscale *** 21.1 (4.7) 10.29–29.54 0.80 18.64 (5.7) 2.8–30.0 0.87
Social & Economic Subscale 22.0 (4.8) 10.71–30.0 0.94 21.29 (5.4) 3.2–30.0 0.82
Psychological & Spiritual Subscale *** 24.5 (4.4) 15.07–30.0 0.81 21.60 (6.7) 0.9–30.0 0.90
Family Subscale 26.8 (3.5) 18.0–30.0 0.91 25.25 (5.1) 0.0–30.0 0.77
Total QOLI Score *** 22.8 (4.0) 14.53–29.67 0.91 20.7 (4.8) 7.3–29.8 0.90
* [38], ** Cronbach's alphas, *** p = 0.005, 0.007, 0.005 respectively: t-test
Table 5: Subjective (Questionnaires) Measures of Nocturnal Sleep and Daytime Sleepiness
Variable Mean Median Mode
Typical sleep duration 377.7 (78.9) 360.0 420.0
How often they felt rested upon awakening in the morning* 3.0 (1.0) 3.0 3.0
How often they had trouble *:
• Falling asleep 2.9 (1.2) 3.0 3.0
• Waking up at night 2.5 (1.2) 2.0 2.0
• Waking up too early and not being able to fall asleep 2.8 (1.1) 3.0 3.0
How often legs kicked or twitched* 1.9 (1.0) 2.0 1.0
How often awake gasping/choking* 1.6 (1.0) 1.0 1.0
How often they napped* 2.7 (1.1) 3.0 3.0
Epworth Sleepiness Scale 7.4 (4.6) 7.0 6.0
* 0 = don't know (classified as missing data and not included in the analyses), 1 = never, 2 = rarely, 3 = sometimes, 4 = most of time, 5 = alwaysHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/68
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0.325, df = 44, p = 0.014), Psychological & Spiritual (rs =
0.319, df = 44, p = 0.015), and Total QLI (rs = 0.332, df =
44, p = 0.012) scores. ESS scores were unrelated to quality
of life measures. Health & Functioning scores were posi-
tively correlated with nocturnal sleep latency (rs = 0.248,
df = 44, p = 0.048) while MSLT scores were positively cor-
related with both Health & Functioning (rs = 0.278, df =
44, p = 0.030) and the total QLI scores (rs = 0.263, df = 44,
p = 0.038). These findings collectively indicate that less
daytime sleepiness was associated with better quality of
life. Although increased numbers of periodic limb move-
ments (PLMI) were associated with lower Health & Func-
tioning (rs = -0.326, df = 44, p = 0.013) and Family (rs = -
0.248, df - 44, p = 0,048) subscale scores, no other rela-
Table 6: Polysomnographic Measures of Nocturnal Sleep and Daytime Sleepiness
Variable Mean (SD) Median
Total Sleep Time (minutes) 335.8 (64.8) 343.0
Sleep Efficiency (%) 78.2 (14.0) 82.4
Sleep Latency (minutes) 31.1 (37.6) 15.9
RDI (events/hour) 13.1 (20.4) 5.4
PLMI (events/hour) 23.0 (36.7) 5.5
PLMs with arousals (events/hour) 9.3 (13.2) 2.4
BAI (events/hour) 30.9 (24.2) 21.1
Mean Sleep Latency (min) 10.2 (4.2) 10.3
RDI = respiratory disturbance index, PLMI = periodic limb movement index, PLMs = periodic limb movements, BAI = brief arousal index
Table 7: Correlations between Measures of Nocturnal Sleep/Daytime Sleepiness and Quality of Life Scores
Variable Health & 
Functioning
Social & Economic Psychological & 
Spiritual
Family Total QLI
Subjective measures (questionnaires) *
Typical sleep duration (n = 46) -- rs = 0.301
P = 0.022
-- -- --
How often they had trouble :
• Falling asleep (n = 45) rs = - 0.387
p = 0.004
rs = - 0.402
p = 0.003
rs = - 0.422
p = 0.002
rs = - 0.497
p = 0.000
rs = - 0.472
p = 0.001
• Waking up at night (n = 44) -- -- -- -- --
• Waking up at night and not being 
able to get back to sleep (n = 45)
rs = - 0.426
p = 0.002
rs = - 0.480
p = 0.000
rs = - 0.373
p = 0.006
rs = - 0.461
p = 0.001
rs = - 0.496
ps = 0.000
How often they felt rested upon 
awakening in the morning (n = 46)
-- rs = 0.325
p = 0.014
rs = 0.319
p = 0.015
-- rs = 0.332
p = 0.012
Nocturnal kicking/twitching (n = 30) -- -- -- -- --
Nocturnal gasping/choking (n = 41) -- -- -- -- --
How often they napped (n = 46) -- -- -- -- --
Epworth Sleepiness Scale (n = 46) -- -- -- -- --
Objective Measures (polysomnography) **
Total Sleep Time (min) -- -- -- -- --
Sleep Efficiency (%) -- -- -- -- --
Sleep Latency (min) rs = 0.248
p = 0.048
-- -- -- --
RDI (events/hour) -- -- -- -- --
PLMI (events/hour) rs = -0.326
p = 0.013
-- -- rs = -0.248
p = 0.048
--
PLMs with arousal (event/hour) rs = -0.247
p = 0.049
-- -- -- --
BAI (events/hour) -- -- -- -- --
Mean Sleep Latency (min) rs = 0.278
p = 0.030
-- -- -- rs = 0.263
p = 0.038
*those subjects who responded that "don't know" (0) were excluded from the analysis, **all analyses include all subjects (n = 46)Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/68
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tionships were noted between PSG and quality of life
measures.
Discussion
Numerous studies in the general population have demon-
strated that poor or reduced amounts of nocturnal sleep
and excessive daytime sleepiness adversely affect a variety
of quality of life and functional health status indicators
[15,46-50]. Both problems have also recently been associ-
ated with cardiovascular disease [46-49], the most com-
mon cause of death in the HD population [42]. However,
although sleep disorders and excessive daytime sleepiness
[51] are very prevalent in the HD population, limited
information is available with regard to the extent to which
these problems affect life quality. Previous reports suggest
that poor subjective sleep[52,53] and sleep-related
breathing disorders [54] have adverse effects, but the
scope of these studies with regard to sleep measures is lim-
ited. Thus, we examined how quality of life is related to
both subjective and objective measures of nocturnal sleep
and daytime sleepiness in a sample of stable HD patients.
Perhaps the most important finding of this study is that
selected indicators of poor nocturnal sleep and increased
daytime sleepiness are associated with reduced quality of
life. Sleep complaints that characterize insomnia [52,55],
including difficulty initiating sleep, early morning awak-
enings, and feeling unrefreshed in the morning, are partic-
ularly important. A recent study by Williams et al. [52],
also noted that complaints of insomnia were associated
with pain, depression, and decreased physical
functioning. These findings suggest that the assessment
and treatment of insomnia-related complaints should be
included in any overall plan of care designed to optimize
quality of life as well as other important clinical out-
comes. Numerous pharmacological and/or cognitive
behavioral techniques are efficacious for treatment of
insomnia but controlled clinical trials designed to evalu-
ate their effectiveness in HD patients remain to be con-
ducted [56-59].
Relationships between TST (measured subjectively or via
PSG) and quality of life measures were not observed,
although subjects obtained an average of only 6 hours of
sleep per night. Excessive daytime sleepiness and
decreased functional status are prevalent in health com-
munity samples that are sleep restricted to this extent
[15,35,46-50,60,61]. We also found that subjective
reports of napping less and PSG measures indicating less
daytime sleepiness were associated with higher quality of
life. Because sleep requirements vary, overall perceived
sleep quality, including subjective responses to sleep and
the ability to function optimally during the day, may be
more important than absolute amount of sleep obtained.
It is interesting to note that Kripke et el. recently demon-
strated an increased risk of mortality associated with
chronic nocturnal sleep periods less than or equal to six
hours [62]. In a 10-year follow-up from NHANES I,
Qureshi et al. also found an increase in stroke in persons
who reported greater than eight hours or less than six
hours per night [63]. Increased napping has also been
associated with increased mortality in the elderly [64,65].
Studies designed to examine the relationship between
specific nocturnal and daytime sleep measures and these
other important clinical outcomes remain to be con-
ducted with the HD population.
Subjects were typically unaware that their legs kicked or
twitched during the night. Nonetheless, PSG revealed that
periodic limb movements were prevalent in this sample.
Greater numbers of movements and movements with
arousals per hour were associated with decreased Health
& Functioning subscale scores, an observation consistent
with previous reports of increased morbidity and mortal-
ity in HD subjects with limb movements [66,67]. Moreo-
ver, it is possible the association of increased limb
movements and decreased family subscale scores may
reflect spousal problems with and/or reaction to noctur-
nal kicking and sleep problems as marital discord is often
seen when one of the partners has a sleep disorder.
Because of the high prevalence of both sleep abnormali-
ties and divorce in the HD population, investigations of
the effects of sleep problems on marital relationships rep-
resents an important area for future research. In contrast
to a previous report [54], we did not find a significant rela-
tionship between apnea and quality of life measures, most
likely because those with a strong history of or receiving
treatment for the condition were systematically elimi-
nated from participation in this study.
Conclusions
In summary, our results support our initial hypotheses
that better sleep quality and less daytime sleepiness are
associated with improved quality of life in stable HD sub-
jects. The overall good health/stability and particular
racial characteristics of the sample limit the generalizabil-
ity of the results to the whole HD patient population. The
small sample size may have also limited our ability to
detect some relationships. Nonetheless, the data support
findings from other studies that have linked general meas-
ures of disturbed sleep in HD subjects with a variety of
quality of life related variables [7,38,68-71]. Some of
these indicated that other clinical outcomes such as a dial-
ysis patient's ability to learn and perform home dialysis
[72-75]; spousal and family normalcy [75,76]; anxiety
and depression [77]; and days of disability [78] are asso-
ciated with reduced sleep quality. Our results suggest that
clinicians should specifically query about nocturnal sleep
quality and daytime sleepiness as they are clinical varia-
bles essential to consider when designing a comprehen-Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/68
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sive treatment program aimed at optimizing the quality of
life of HD patients.
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